Search Results
Filter Results:
People (1231)
Demian Ahn
Partner
Demian Ahn is a member of the firm’s data, privacy, and cybersecurity practice based in Washington, D.C. He leads the firm’s incident response practice and advises companies on compliance, regulatory, and crisis management matters relating to emerging technologies of all kinds.
Josephine Aiello LeBeau
Partner
Josephine focuses on matters related to compliance and enforcement of U.S. export control and sanctions.
Ali R. Alemozafar
Partner
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
Lester Ang
Partner
Lester Ang is a corporate and securities partner in the Palo Alto office of Wilson Sonsini, where he works with private and public technology and life sciences companies through all stages of their growth, as well as with venture capital firms and private equity firms.
Brian Appel
Partner
Brian Appel is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he practices corporate and securities law. He advises companies on general corporate matters, including formation and operation, corporate governance, debt and equity financings, mergers and acquisitions, and securities-related matters. He has assisted early-stage companies in numerous capital-raising transactions, including venture capital financings.
Matthew A. Argenti
Partner
Matt is an experienced patent litigatior with an focus on post-grant review proceedings before the PTAB.
Hin Au
Partner
Hin Au is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.
Christine K. Au-Yeung
Partner
Christine Au-Yeung is a partner in the San Francisco and Palo Alto offices of Wilson Sonsini Goodrich & Rosati, where she focuses on trademark, copyright, and advertising law. She counsels clients on all aspects of brand protection in the U.S. and throughout the world, including clearance and selection of trademarks, prosecution of trademark applications, licensing, and the resolution of trademark infringement and domain name disputes. She also advises clients on advertising issues, including TCPA compliance related to marketing calls and texts, as well as strategies on promotions such as sweepstakes and contests.
Colleen Bal
Partner
Colleen is a nationally recognized trial lawyer with a proven track record of handling difficult and high-profile cases for leading technology, life sciences, and financial companies.
Services (114)
Insights (5051)
Client Highlights
11.11.26
Wilson Sonsini Advises PacBio on $100 Million At-the-Market Stock Offering
On November 10, 2026, Pacific Biosciences of California, Inc. (PacBio), developer of the world’s most advanced sequencing technologies, entered into a sales agreement with Allen & Company LLC to offer up to $100 million of its common stock through an at-the-market program. Under the terms of the agreement, PacBio may offer and sell shares of its common stock having an aggregate offering price of up to $100 million from time to time through or to Allen & Company LLC, acting as PacBio’s sales agent or principal. Wilson Sonsini Goodrich & Rosati advised PacBio on the transaction.
PacBio intends to use the proceeds from this offering, together with existing cash, cash equivalents, and investments, for research and development and working capital and general corporate purposes.
The Wilson Sonsini team that advised PacBio on the transaction included Andrew Hoffman, Zachary Myers, Annie Giomi, James Keegan, and Mounika Yepuri.
For more information, please see PacBio’s prospectus supplement.
PacBio intends to use the proceeds from this offering, together with existing cash, cash equivalents, and investments, for research and development and working capital and general corporate purposes.
The Wilson Sonsini team that advised PacBio on the transaction included Andrew Hoffman, Zachary Myers, Annie Giomi, James Keegan, and Mounika Yepuri.
For more information, please see PacBio’s prospectus supplement.
Newsletters
11.10.26
European Antitrust Bimonthly Bulletin – September/October 2026
The firm is pleased to distribute the European Antitrust Bimonthly Bulletin, which distills the major antitrust developments in Europe over the past two months into concise and actionable takeaways. Companies operating in, or transacting with, Europe should take note of this quarter's developments in merger enforcement, digital markets regulation, and AI-related antitrust scrutiny.
Client Highlights
11.10.26
Firm Represents Veteran Ventures Capital as Lead Investor in $6.95 Million Aformic Financing
On November 4, 2026, Veteran Ventures Capital (VVC) announced that it led a $6.95 million investment in Aformic, a robotics company that designs and deploys autonomous mobile robots and fleet-management software. Wilson Sonsini Goodrich & Rosati advised VVC on the transaction.
Client Highlights
11.10.26
Wilson Sonsini Advises Ancep on $8.5 Million Funding Round
On November 10, 2026, Ancep, a London-based start-up building artificial intelligence (AI) agents for commercial insurance brokers, emerged from stealth and announced it raised $8.5 million in a funding round led by Creandum. The round also included participation from Kleiner Perkins and Vicus Ventures, alongside angel investors including Christa Davies, former chief financial officer of Aon, and operators from OpenAI, Anthropic, and Google DeepMind. Ancep will use the new funds to support growth and hiring. Wilson Sonsini Goodrich & Rosati advised Ancep on the transaction.
Client Highlights
11.10.26
Wilson Sonsini Advises Graphon Labs on $35 Million Series A
On November 10, 2026, Graphon Labs, an applied artificial intelligence (AI) lab building Persistent Intelligence to power the next generation of AI agents and accelerate progress toward artificial general intelligence, announced a $35 million Series A led by RRE Ventures, with participation from HP, Energy Impact Partners, Hitachi Ventures, and Gaia VC. Wilson Sonsini Goodrich & Rosati advised Graphon Labs on the transaction.
Bylined Articles
11.09.26
Law360 Article: “What FTC Publicis Deal Means for Data Infrastructure M&A”
Wilson Sonsini partners Michelle Yost Hale and Matthew McDonald recently authored a Law360 article examining what the Federal Trade Commission’s (FTC) proposed consent order in Publicis Groupe SA’s $2.2 billion acquisition of LiveRamp means for data infrastructure mergers and acquisitions. The piece explains that the October 19 order resolves a purely vertical theory of harm centered on Publicis’ potential control over LiveRamp’s previously neutral data connectivity services, and requires Publicis, for five years, to provide nondiscriminatory access, maintain firewalls for customer data, and submit to compliance audits.
Client Highlights
11.09.26
Wilson Sonsini Advises HZO on Acquisition by Forge Nano
On November 5, 2026, Forge Nano Holdings, Inc. (Forge Nano), a semiconductor equipment and advanced materials company whose Atomic Layer Deposition (ALD) technology serves AI-era chip manufacturing and defense battery applications, announced that it has completed the acquisition of HZO, Inc., a leading provider of protective nanocoatings for electronics. The combination pairs Forge Nano’s ALD platform with HZO’s high-volume Parylene and thin-film protective coating business and its blue-chip customer base in the consumer electronics, energy, IoT, medical, and automotive industries. Wilson Sonsini Goodrich & Rosati advised HZO on the transaction.
Client Highlights
11.09.26
Wilson Sonsini Advises KymaThera on IP Matters Related to $80 Million Series B
On October 6, 2026, KymaThera, a biotechnology company developing next-generation precision medicines for genetically defined diseases, announced the closing of an $80 million Series B financing led by Alta Partners, with participation from Venrock, Foresite Capital, J. Wood Capital, and others. Wilson Sonsini Goodrich & Rosati advised KymaThera on intellectual property matters related to the financing.
Client Highlights
11.09.26
Wilson Sonsini Advises Skydio on $1.2 Billion Axon Investment
On November 5, 2026, Axon, a global leader in public safety technology, announced an additional $1.2 billion investment in Skydio, the largest U.S.-based drone manufacturer and a world leader in flying robots. The agreement, which will add approximately 20 percent to Axon's fully diluted ownership in Skydio at a $5.2 billion pre-money valuation, builds on a partnership that is already bringing Skydio drones to public safety agencies across the U.S., marking a major expansion of Axon's Drone as First Responder (DFR) program. Axon will also become Skydio's exclusive distributor for public safety in the U.S. and Canada. Wilson Sonsini Goodrich & Rosati advised Skydio on the transaction.
Events (1969)
Affiliated Programs
12.11.26
Behind the Raise: The Financial Journey for Life Science Founders
Wilson Sonsini is pleased to sponsor the University of San Diego Knauss School of Business Center for Applied Finance symposium, which will focus on the key considerations and strategies for raising capital in the early stages of building a life sciences company.
Speaking Engagements
12.08.26
PLI's Tax Strategies for Corporate Acquisitions, Dispositions, Spin-Offs, Joint Ventures, Financings, Reorganizations & Restructurings 2026
Practising Law Institute (PLI) features specialized sessions on tax strategies for financially troubled businesses within its premier annual conference series on Tax Strategies for Corporate Acquisitions, Dispositions, Spin-Offs, Joint Ventures, Financings, Reorganizations & Restructurings. These programs focus on navigating net operating losses (NOLs), debt restructurings, and corporate distress under complex federal tax rules.
Affiliated Programs
12.03.26
27th Annual Berkeley-Stanford Advanced Patent Law Institute
Wilson Sonsini Goodrich & Rosati is pleased to support the 27th Annual Berkeley-Stanford Advanced Patent Law Institute, a premier program that brings together patent litigators, prosecutors, senior in-house intellectual property (IP) counsel, academics, and judges for two days of candid, practical discussion of where patent law is headed.
Speaking Engagements
Wednesday, December 2, 2026
Practical Applications of AI in Litigation: Claude, CoCounsel, and Lexis+ AI/LexText
Wilson Sonsini litigation attorney Tamara Lemmon will present National Business Institute’s webinar on “Practical Applications of AI in Litigation: Claude, CoCounsel, and Lexis+ AI/LexText”. This CLE will compare three AI platforms and show where each can fit into a litigation practice. Through practical demonstrations, Tamara will cover how AI can be used to analyze pleadings and case documents, organize facts, build chronologies, conduct legal research, review discovery, identify inconsistencies, prepare witnesses, develop deposition outlines, and create litigation work product.
Speaking Engagements
Tuesday, December 1, 2026
Informa Connect's CompLaw: Pharma 2026
Wilson Sonsini Of Counsel Andrew Morrison joins the "Product Bundling: Competition Law Concerns" panel at CompLaw: Pharma, hosted by Informa Connect. Andrew is joined by Luca Arnaudo, Senior Officer at the Italian Competition Authority, and Andrea Bazzotti, European Legal Counsel at Ultragenyx Europe GmbH.
Affiliated Programs
Tuesday, December 1, 2026
The Competition Law & Artificial Intelligence Summit 2026, ThoughtLeaders4
Wilson Sonsini partner Jindrich Kloub is moderating the "Insights from EU Member State Regulators" session at The Competition Law & Artificial Intelligence Summit, hosted by ThoughtLeaders4. Jindrich is joined by Yann Guthmann, Head of the Digital Economy Unit at Autorité de la concurrence.
Speaking Engagements
Monday, November 23, 2026
PLI's Twenty-Fourth Annual Directors' Institute on Corporate Governance
Boards must navigate a fast-changing environment that now spans corporate governance, shareholder activism, fiduciary duties, legal and business risk oversight, privacy, cybersecurity, AI governance, and criminal and regulatory enforcement. At this program, leading corporate governance experts, including directors, government officials, corporate counsel, and consultants, will share practical perspectives on the issues shaping board oversight today: the 2026 proxy season and evolving activist strategies, corporate law developments, emerging technology risks, enforcement priorities, and the topics that keep directors up at night.